Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA:600521)
China
· Delayed Price · Currency is CNY 15.81
-0.18 (-1.13%)
At close: Mar 9, 2026
SHA:600521 Revenue
Zhejiang Huahai Pharmaceutical had revenue of 1.89B CNY in the quarter ending September 30, 2025, a decrease of -10.70%. This brings the company's revenue in the last twelve months to 8.71B, down -6.85% year-over-year. In the year 2024, Zhejiang Huahai Pharmaceutical had annual revenue of 9.55B with 14.91% growth.
Revenue (ttm)
8.71B
Revenue Growth
-6.85%
P/S Ratio
2.71
Revenue / Employee
960.69K
Employees
9,065
Market Cap
23.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.55B | 1.24B | 14.91% |
| Dec 31, 2023 | 8.31B | 42.97M | 0.52% |
| Dec 31, 2022 | 8.27B | 1.62B | 24.42% |
| Dec 31, 2021 | 6.64B | 158.36M | 2.44% |
| Dec 31, 2020 | 6.49B | 1.10B | 20.36% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dizal (Jiangsu) Pharmaceutical | 801.14M |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.02B |
| Wedge Industrial | 1.24B |
| Hubei Jumpcan Pharmaceutical | 6.14B |
| Chengdu Kanghong Pharmaceutical Group | 4.67B |
| Jilin Aodong Pharmaceutical Group | 2.34B |
| Kangmei Pharmaceutical | 5.28B |
| Tasly Pharmaceutical Group | 8.24B |